The treatment of central nervous system (CNS) disorders always remains a challenge for the
researchers. The presence of various physiological barriers, primarily the blood–brain …

Blood–brain barrier (BBB) together with enzymes restricts the entry of substances for
maintaining the internal milieu of the brain. Because of the presence of multiple endogenous …

In recent years, the researchers and drug designers have given growing attention to new
nanotechnology strategies to improve drug delivery to the central nervous system (CNS) …

Blood-brain barrier (BBB) provides restrictions for the transportation of various therapeutic
agents to the brain. Efforts to directly target the brain by olfactory as well as trigeminal nerve …

Many of the therapeutics used for the treatment of brain disorders are not effective and not
delivered to the brain due to the complex structure and its barriers. In recent years, many …

The blood–brain barrier (BBB) restricts the transport of potential therapeutic moieties to the
brain. Direct targeting the brain via olfactory and trigeminal neural pathways by passing the …

Neurodegenerative diseases including Alzheimer's disease, Parkinson's disease,
Huntington disease and amyotrophic lateral sclerosis throw a heavy burden on families and …

The blood–brain barrier (BBB) is a barrier that separates the blood from the brain tissue and
possesses unique characteristics that make the delivery of drugs to the brain a great …

The administration of drugs to the central nervous system (CNS) is primarily controlled by
the blood-brain barrier (BBB), a structure that prevents the passage of foreign compounds …

The possibility to treat central nervous system (CNS) disorders is strongly limited by the poor
access of many therapeutic agent to the target tissues. This is mainly due to the presence of …